What is Madrigal Pharmaceuticals Inc (MDGL) stock price today?

Madrigal Pharmaceuticals Inc (MDGL) currently trades at $518.58 per share. The stock has a market capitalization of $11.96B and a P/E ratio of —x.

Is MDGL stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Madrigal Pharmaceuticals Inc has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is 0.22.

What is Madrigal Pharmaceuticals Inc's revenue and earnings?

Madrigal Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $958.40M with profit margins of -30.10%. Earnings per share (EPS) is $-12.87.

Is Madrigal Pharmaceuticals Inc financially healthy?

Madrigal Pharmaceuticals Inc's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of 0.22 places it in the distress.

MDGL

Madrigal Pharmaceuticals Inc

NASDAQ: MDGL · HEALTHCARE · BIOTECHNOLOGY

$518.58

+0.37% today

Updated 2026-04-29

Market cap

$11.96B

P/E ratio

—

P/S ratio

12.48x

EPS (TTM)

$-12.87

Dividend yield

—

52W range

$265 – $615

Volume

0.4M

Market cap

$11.96B

P/E ratio

—

P/S ratio

12.48x

EPS (TTM)

$-12.87

Dividend yield

—

52W range

$265 – $615

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.3

Growth

5.8

Quality

C+

2.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

0.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$672.79

+29.74%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy11 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 210.80% QoQ

Risks

- Altman Z 0.22 — distress zone

- Thin margins at -30.10%

- Negative free cash flow $-133.85M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$180.13M	$958.40M	$958.40M
Net income	$-295.35M	$-373.63M	$-465.89M	$-288.28M	$-58.58M
EPS	—	—	—	—	$-12.87
Free cash flow	$-225.07M	$-325.71M	$-457.03M	$-190.02M	$-133.85M
Profit margin	—	—	-258.64%	-30.08%	-30.10%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-06	TAUB, REBECCA	Sale	491	$431.94
2026-03-06	SIBOLD, WILLIAM JOHN	Sale	1,663	$431.94
2026-03-06	KELLEY, SHANNON T	Sale	360	$431.94

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MDGL	$11.96B	31	6.3	2.0	5.0	5.8	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Madrigal Pharmaceuticals Inc trades at $518.58. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.22, it sits in the distress. TTM revenue stands at $958.40M. with profit margins at -30.10%.

Frequently asked questions

What is Madrigal Pharmaceuticals Inc's stock price?

Madrigal Pharmaceuticals Inc (MDGL) trades at $518.58.

Is Madrigal Pharmaceuticals Inc overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of Madrigal Pharmaceuticals Inc (MDGL)?

The analyst target price is $672.79, representing +29.7% upside from the current price of $518.58.

What is Madrigal Pharmaceuticals Inc's revenue?

TTM revenue is $958.40M.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

0.22 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio12.48x

ROE-42.50%

Beta-1.01

50D MA$480.41

200D MA$467.28

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.4M

Performance

1 week-0.03%

1 month-0.93%

3 months+4.83%

YTD-10.95%

1 year—

3 years—

5 years—

Compare

MDGL vs LLY →MDGL vs JNJ →MDGL vs ABBV →Stock screener →